Physician profile
Alexander Kessler
NPI 1518949528
$3,326.34
in general payments reported to CMS, 2019-2025
42 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $408 · 2021: $449 · 2022: $498 · 2023: $563 · 2024: $424 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $369.47 | 2019-2025 | Arikayce, Brinsupri |
| Novo Nordisk INC | $325.72 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $235.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $184.91 | 2019-2024 | Zinplava, Recarbrio, Zerbaxa |
| Abbvie INC. | $177.37 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $163.86 | 2021-2022 | |
| Pfizer INC. | $161.76 | 2019-2025 | |
| La Jolla Pharmaceutical Company | $121.63 | 2021-2025 | Xerava, Zevtera |
| Viiv Healthcare Company | $120.94 | 2022-2024 | Dovato |
| Lilly USA, LLC | $110.20 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $104.20 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $103.66 | 2023-2025 | Gemtesa |
| Melinta Therapeutics, LLC | $92.83 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Grifols USA, LLC | $92.47 | 2023-2025 | Xembify |
| Allergan, INC. | $91.46 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.